Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 16 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 14, 2017. Details of Allegra Hives's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(8 years ago) |
Expired
|
| US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(8 years ago) |
Expired
|
|
US5932247 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(10 years ago) |
Expired
|
|
US5855912 (Pediatric) | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(10 years ago) |
Expired
|
|
US6113942 (Pediatric) | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(10 years ago) |
Expired
|
| US5932247 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(10 years ago) |
Expired
|
| US6113942 | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(10 years ago) |
Expired
|
| US5855912 | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(10 years ago) |
Expired
|
|
US7135571 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US5578610 (Pediatric) | Piperidine derivatives |
May, 2014
(11 years ago) |
Expired
|
| US7135571 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(11 years ago) |
Expired
|
| US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(11 years ago) |
Expired
|
| US5578610 | Piperidine derivatives |
Nov, 2013
(11 years ago) |
Expired
|
|
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
|
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Allegra Hives's patents.
Latest Legal Activities on Allegra Hives's Patents
Given below is the list of recent legal activities going on the following patents of Allegra Hives.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 17 Dec, 2018 | US7135571 |
| Maintenance Fee Reminder Mailed
Critical | 25 Jun, 2018 | US7135571 |
| Expire Patent
Critical | 19 Dec, 2014 | US7138524 |
| Petition Decision - Granted
Critical | 31 Jan, 2008 | US7135571 |
| Mail-Petition Decision - Granted | 31 Jan, 2008 | US7135571 |
| Petition Entered | 14 Jan, 2008 | US7135571 |
| Post Issue Communication - Certificate of Correction | 05 Jan, 2007 | US7135571 |
| Patent Issue Date Used in PTA Calculation
Critical | 21 Nov, 2006 | US7138524 |
| Recordation of Patent Grant Mailed
Critical | 21 Nov, 2006 | US7138524 |
| Patent Issue Date Used in PTA Calculation
Critical | 14 Nov, 2006 | US7135571 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Allegra Hives and ongoing
litigations to
help you estimate the early arrival of Allegra Hives generic.
Allegra Hives's Litigations
Allegra Hives been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 02, 1999, against patent number US6037353. The petitioner , challenged the validity of this patent, with YOUNG as the respondent. Click below to track the latest information on how companies are challenging Allegra Hives's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6037353 | November, 1999 |
Decision
(02 Nov, 1999) | YOUNG | |
US patents provide insights into the exclusivity only within the United States, but
Allegra Hives is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Allegra Hives's family patents as well as insights into
ongoing legal events
on those patents.
Allegra Hives's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Allegra Hives's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 14, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Allegra Hives Generic API suppliers:
Fexofenadine Hydrochloride is the generic name for the brand Allegra Hives. 15 different companies have already filed for the generic of Allegra Hives, with Dr Reddys Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Allegra Hives's generic
How can I launch a generic of Allegra Hives before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Allegra Hives's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Allegra Hives's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Allegra Hives -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 30 mg, 60 mg and 180 mg |
Alternative Brands for Allegra Hives
Allegra Hives which is used for relieving symptoms of respiratory allergies and hives in adults and children., has several other brand drugs in the same treatment category and using the same active ingredient (Fexofenadine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi |
| |||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Fexofenadine Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Chattem Sanofi |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fexofenadine Hydrochloride, Allegra Hives's active ingredient. Check the complete list of approved generic manufacturers for Allegra Hives
About Allegra Hives
Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for relieving symptoms of respiratory allergies and hives in adults and children. Allegra Hives uses Fexofenadine Hydrochloride as an active ingredient. Allegra Hives was launched by Chattem Sanofi in 2011.
Approval Date:
Allegra Hives was approved by FDA for market use on 24 January, 2011.
Active Ingredient:
Allegra Hives uses Fexofenadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fexofenadine Hydrochloride ingredient
Treatment:
Allegra Hives is used for relieving symptoms of respiratory allergies and hives in adults and children.
Dosage:
Allegra Hives is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 60MG | TABLET | Discontinued | ORAL |
| 180MG | TABLET | Over the counter | ORAL |